Industry news

Study confirms SalivaMAX™ is safe & effective for the reduction of oral mucositis

Study confirms SalivaMAX™ is clinically proven as a safe and effective method for the reduction of oral mucositis

HOUSTON – April 13, 2018 – With the advancements in oncology drugs over the past decade, new discoveries have eliminated some of the most common side effect such as nausea with chemotherapy. Unfortunately for the patient, this has resulted in oral mucositis now being one of the most common side effects for oncology treatments. Oral mucositis has a significantly negative impact on a patients’ quality of life and pain as well as their treatment costs. In efforts to continue to enhance patient care, Forward Science partnered with a regional cancer center in Colorado to conduct a study for the use of SalivaMAX for the mitigation of oral mucositis.

SalivaMAX, manufactured by Forward Science, is an FDA Cleared prescription rinse that is indicated for both xerostomia and mucositis. SalivaMAX is currently being used at some of the top cancer centers in the nation; however, Forward Science wanted to quantify the success of SalivaMAX for use in oncology. The control, a soda / salt rinse, was compared to a powered supersaturated calcium phosphate rinse (SSCPR), SalivaMAX. “Not only has SalivaMAX reduced the severity of oral mucositis, it has pushed back the onset by almost one week” reported one of the Oncology Clinicians during the study. The retrospective study published in the Journal of Cancer Therapy demonstrated that the powdered supersaturated calcium phosphate rinse was a statistically significant more effective method of oral mucositis mitigation than the standard of care.

“All of us at Forward Science are proud of the results that SalivaMAX brings patients.” explains Brian Pikkula, PhD, President and Co-Founder of Forward Science. “We think it’s especially important to inform the clinical community of the efficacy of SalivaMAX (a SSCPR), and really, there’s no better way than a study published in a peer reviewed journal. We hope this data will help turn the tide so that SalivaMAX is recognized as the standard of care in oncology centers.” With continued evidence that SalivaMAX is an effective method to treat both xerostomia and mucositis, Forward Science will strive to further to educate clinicians that SalivaMAX should replace soda / salt rinses as the standard of care for oral mucositis treatment.


About Forward Science
Forward Science is a privately held biotechnology company based in Houston, Texas. OralID, Forward Science’s flagship product, is an award winning oral cancer screening device that allows clinicians to discover abnormalities that may not be seen under traditional white light examinations. With the success of OralID, Forward Science continued its focus to advance healthcare in oral oncology and launched advanced diagnostic tests (CytID, hpvID, phID, PathID) and treatment options (SalivaMAX, SalivaCAINE). All Forward Science products are designed, developed, and manufactured by their team in-house, ensuring the highest quality of product to go along with their superior customer service. Forward Science has quickly evolved into the industry leader for oral oncology.

To learn more about OralID, or any of Forward Science’s products, please visit https://forwardscience.com or call 855-696-7254.

Download the full report here.

 

Leave a Comment